FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317107798> ?p ?o ?g. }

• W4317107798 endingPage "A024" @default.
• W4317107798 startingPage "A024" @default.
• W4317107798 abstract "Abstract Background: Effective treatment of metastatic disease remains a major challenge in the improvement of patient outcomes in osteosarcoma (OS). Novel anti-metastatic therapies are needed to treat distant metastases. To this end, the current research evaluates whether targeting the dysregulated mRNA translation machinery in OS can inhibit metastases. Hypothesis: We hypothesize that mRNA translation factors present at an abnormally high abundance in OS cells support the rapid synthesis of cytoprotective proteins that are needed to survive in the oxidative stress-rich microenvironment of the lung. Experimental Approach: Databases of OS cell lines and patient tumor data (A. Sweet-Cordero, UCSF) were queried to identify mRNA translation factors with abnormal transcript levels. A limited drug screen of small molecule inhibitors (SMIs) against identified candidates was carried out to evaluate IC50 values in metastatic OS cells. A candidate inhibitor identified from these data was further characterized for synergy with chemical inducers of oxidative stress (e.g. tert-butylhydroquinone [tBHQ]) that mimics conditions encountered in the lung. Drug combination studies examined 2D and 3D tumor spheroid growth, cellular oxidative stress, and PARP-cleavage, under +/- inhibitor and +/- oxidative stress conditions. Metastatic OS cells were engineered to express an antioxidant response element (ARE)-mCherry fluorescent reporter to directly monitor the antioxidant response by fluorescence microscopy. Polysome profiling was used to assess inhibitor-mediated changes in global mRNA translation. The anti-metastatic activity of the inhibitor was tested in the ex vivo pulmonary metastasis assay (PuMA) and in in vivo metastasis models. Results: From cell and patient sample screening, eIF4A1/2 was identified as being abnormally regulated in metastatic OS cells. The SMI, CR-1-31B, specifically targets eIF4A1/2 and was found to have an IC50 of just 8 nM. CR-1-31B was found to inhibit tumor cell growth in 2D and 3D, increase cellular oxidative stress, and enhance PARP-cleavage, but only under oxidative stress conditions. Western analysis of tBHQ-treated metastatic OS cells with the ARE-mCherry reporter confirmed that the temporal expression of mCherry correlated with the upregulation of Nuclear factor erythroid 2-related factor-2 (Nrf2), a key transcriptional regulator of the antioxidant response. CR-1-31B blunted the upregulation of the antioxidant response in 2D and 3D tumor growth conditions with oxidative stress. CR-1-31B, in a dose-dependent manner, decreased the amount of polysomal mRNAs. CR-1-31B reduced the lung tumor burden in the ex vivo PuMA model, delayed primary tumor growth, and reduced lung metastases in in vivo xenograft OS models. Conclusions: Our data demonstrates that dysregulated mRNA translation is a metastatic vulnerability that can be exploited with SMIs. Altogether, these data support the inhibition of metastatic OS by CR-1-31B, highlighting the potential therapeutic utility of this selective translation inhibitor. Citation Format: Michael M. Lizardo, Christopher Hughes, Yue Zhou Huang, Alberto Delaidelli, Taras Shyp, Haifeng Zhang, Sol Snir Shaool, Poul H. Sorensen. A potent eIF4A1/2 inhibitor CR-1-31B down-modulates the antioxidant stress response in osteosarcoma cells and inhibits in vivo lung metastases [abstract]. In: Proceedings of the AACR Special Conference: Cancer Metastasis; 2022 Nov 14-17; Portland, OR. Philadelphia (PA): AACR; Cancer Res 2022;83(2 Suppl_2):Abstract nr A024." @default.
• W4317107798 created "2023-01-18" @default.
• W4317107798 creator A5004996363 @default.
• W4317107798 creator A5011919938 @default.
• W4317107798 creator A5030138633 @default.
• W4317107798 creator A5040570196 @default.
• W4317107798 creator A5051219791 @default.
• W4317107798 creator A5052593466 @default.
• W4317107798 creator A5077817320 @default.
• W4317107798 creator A5083608565 @default.
• W4317107798 date "2023-01-15" @default.
• W4317107798 modified "2023-09-26" @default.
• W4317107798 title "Abstract A024: A potent eIF4A1/2 inhibitor CR-1-31B down-modulates the antioxidant stress response in osteosarcoma cells and inhibits <i>in vivo</i> lung metastases" @default.
• W4317107798 doi "https://doi.org/10.1158/1538-7445.metastasis22-a024" @default.
• W4317107798 hasPublicationYear "2023" @default.
• W4317107798 type Work @default.
• W4317107798 citedByCount "0" @default.
• W4317107798 crossrefType "journal-article" @default.
• W4317107798 hasAuthorship W4317107798A5004996363 @default.
• W4317107798 hasAuthorship W4317107798A5011919938 @default.
• W4317107798 hasAuthorship W4317107798A5030138633 @default.
• W4317107798 hasAuthorship W4317107798A5040570196 @default.
• W4317107798 hasAuthorship W4317107798A5051219791 @default.
• W4317107798 hasAuthorship W4317107798A5052593466 @default.
• W4317107798 hasAuthorship W4317107798A5077817320 @default.
• W4317107798 hasAuthorship W4317107798A5083608565 @default.
• W4317107798 hasConcept C104317684 @default.
• W4317107798 hasConcept C105580179 @default.
• W4317107798 hasConcept C121608353 @default.
• W4317107798 hasConcept C126322002 @default.
• W4317107798 hasConcept C149364088 @default.
• W4317107798 hasConcept C150903083 @default.
• W4317107798 hasConcept C185592680 @default.
• W4317107798 hasConcept C207001950 @default.
• W4317107798 hasConcept C26291073 @default.
• W4317107798 hasConcept C2776151105 @default.
• W4317107798 hasConcept C2779013556 @default.
• W4317107798 hasConcept C2779638656 @default.
• W4317107798 hasConcept C502942594 @default.
• W4317107798 hasConcept C55493867 @default.
• W4317107798 hasConcept C71924100 @default.
• W4317107798 hasConcept C86803240 @default.
• W4317107798 hasConcept C98274493 @default.
• W4317107798 hasConceptScore W4317107798C104317684 @default.
• W4317107798 hasConceptScore W4317107798C105580179 @default.
• W4317107798 hasConceptScore W4317107798C121608353 @default.
• W4317107798 hasConceptScore W4317107798C126322002 @default.
• W4317107798 hasConceptScore W4317107798C149364088 @default.
• W4317107798 hasConceptScore W4317107798C150903083 @default.
• W4317107798 hasConceptScore W4317107798C185592680 @default.
• W4317107798 hasConceptScore W4317107798C207001950 @default.
• W4317107798 hasConceptScore W4317107798C26291073 @default.
• W4317107798 hasConceptScore W4317107798C2776151105 @default.
• W4317107798 hasConceptScore W4317107798C2779013556 @default.
• W4317107798 hasConceptScore W4317107798C2779638656 @default.
• W4317107798 hasConceptScore W4317107798C502942594 @default.
• W4317107798 hasConceptScore W4317107798C55493867 @default.
• W4317107798 hasConceptScore W4317107798C71924100 @default.
• W4317107798 hasConceptScore W4317107798C86803240 @default.
• W4317107798 hasConceptScore W4317107798C98274493 @default.
• W4317107798 hasIssue "2_Supplement_2" @default.
• W4317107798 hasLocation W43171077981 @default.
• W4317107798 hasOpenAccess W4317107798 @default.
• W4317107798 hasPrimaryLocation W43171077981 @default.
• W4317107798 hasRelatedWork W2004172311 @default.
• W4317107798 hasRelatedWork W2011115045 @default.
• W4317107798 hasRelatedWork W2013765863 @default.
• W4317107798 hasRelatedWork W2073863642 @default.
• W4317107798 hasRelatedWork W2084547689 @default.
• W4317107798 hasRelatedWork W2463515876 @default.
• W4317107798 hasRelatedWork W2913223560 @default.
• W4317107798 hasRelatedWork W2946814605 @default.
• W4317107798 hasRelatedWork W4235616939 @default.
• W4317107798 hasRelatedWork W4312094460 @default.
• W4317107798 hasVolume "83" @default.
• W4317107798 isParatext "false" @default.
• W4317107798 isRetracted "false" @default.
• W4317107798 workType "article" @default.